The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).
 
Eric Jonasch
Consulting or Advisory Role - Cerulean Pharma; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Onyx; Pfizer
Travel, Accommodations, Expenses - Cerulean Pharma; Novartis; Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
 
Bernard Escudier
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
David W Markby
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Jace Nielsen
Consulting or Advisory Role - Exelixis
 
Steven Lacy
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Research Funding - Exelixis
Patents, Royalties, Other Intellectual Property - Exelixis
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy